After stalling in the U.S., FibroGen anemia drug wins European nod and $120M partner payout
The drug is approved for chronic kidney disease patients in Europe, Japan, China, Chile and South Korea but was rejected earlier this month by U.S. regulators.
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Ron Leuty Source Type: news
More News: Anemia | Biotechnology | Chile Health | China Health | Chronic Kidney Disease | Health Management | Japan Health | South Korea Health | Urology & Nephrology